Company Profile

Now doing business as Taxus Cardium Pharmaceuticals Group Inc.OTCMKTS:CRXM), the firm has a complex history. In October 2005 - the then Cardium THerapeutics acquired a portfolio of biologic growth factors from the Schering AG Group for potential use in treating ischemic and other cardiovascular conditions, including Generx®, a product candidate being developed for patients with chronic myocardial ischemia. In March 2006 - Acquired technologies and products of InnerCool Therapies, Inc., a medical technology company in the emerging field of therapeutic hypothermia or patient temperature modulatioin August 2006, Cardium Therapeutics, Inc had acquired the Tissue Repair Company. In 2005, Cardium Therapeutics had effected a reverse merger with public shell company Aries Ventures to permit the firm publicly to trade. In August 2006, then Cardium Therapeutics, Inc acquired the Tissue Repair Company. In 2005, Cardium Therapeutics did a reverse merger with public shell company Aries Ventures to permit the firm publicly to trade. Now trading as Taxus Cardium Pharmaceutical group (OTCMKTS:CRXM). Cardium Therapeutics is organzied around acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium’s investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In May 2009, Cardium announced completion of the enrollment for the Matrix Phase 2b clinical study to evaluate the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfo